Ernexa Therapeutics Inc.ERNANASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR-20.3%
5Y CAGR+104.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-20.3%/yr
Quarterly compound
5Y CAGR
+104.0%/yr
Recent deceleration
Percentile
P77
Within normal range
vs 5Y Ago
35.3x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 20.31% |
| Q2 2025 | 8.39% |
| Q1 2025 | -1.22% |
| Q4 2024 | -19.39% |
| Q3 2024 | 54.19% |
| Q2 2024 | 14.79% |
| Q1 2024 | -0.38% |
| Q4 2023 | -4.72% |
| Q3 2023 | -21.02% |
| Q2 2023 | 14.43% |
| Q1 2023 | -12.22% |
| Q4 2022 | 42.96% |
| Q3 2022 | 40.17% |
| Q2 2022 | -120.46% |
| Q1 2022 | 26.23% |
| Q4 2021 | 90.11% |
| Q3 2021 | -761.64% |
| Q2 2021 | -12.24% |
| Q1 2021 | -304.27% |
| Q4 2020 | -9.92% |
| Q3 2020 | 0.58% |
| Q2 2020 | -99.03% |
| Q1 2020 | 0.00% |